Organisation paid for research Program year 2025 Source: CMS Open Payments

Cfagi LLC

Neither a doctor nor a teaching hospital

Research payments

$197,521

75 payments

Through program year 2025, Cfagi LLC is reported as receiving $197,521 in research payments, across 75 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $48,958 24
2024 Research $52,743 18
2023 Research $48,229 13
2022 Research $23,559 10
2021 Research $20,533 9
2020 Research $3,500 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. AbbVie, Inc. $183,029 71 payments
  2. Bausch Health US, LLC $10,992 3 payments
  3. Janssen Research & Development, LLC $3,500 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) $82,950 26 payments
  2. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $19,764 4 payments
  3. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease $17,497 12 payments
  4. Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis $14,080 4 payments
  5. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease $11,710 4 payments
  6. A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (Mt-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC) $10,992 3 payments
  7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis $9,464 4 payments
  8. A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis $8,127 1 payment
  9. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) $5,382 1 payment
  10. M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease $5,130 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record